retatrutide peptide clinical trials weight loss New GLP-1 obesity drug, retatrutide, shows added benefits Retatrutide Peptide: The Breakthrough Triple-Hormone – Retatrutide FDA Approval Status 2026:

As always, if you have any questions, please reach out to your Rose Street Advisors Relationship Manager.

Slominski A, Wortsman J, Paus R, Elias PM, Tobin DJ, Feingold KR

GLP-1 blocks the release of glucagon and prevents glucose from reaching the bloodstream

While rare cases have been reported, studies like SURMOUNT-1 show similar pancreatitis rates in those receiving placebo

Michael Weintraub, an endocrinologist at NYU Langone Health

Understanding the evidence, safety considerations, and lack of proven synergistic benefit is essential for informed clinical decision-making when patients consider combining these treatments